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Purpose: To determine whether capecitabine (X), combined with docetaxel (T) following doxorubicin (A) and
cyclophosphamide (C), enhanced the pathological complete response (pCR) in the breast and axillary lymph nodes
(ALNs) of women with large or locally advanced breast cancers (LLABCs) improving outcome, and the effect on
quality of life (QoL).
Patients and methods: 117 women were enrolled, 112 randomised to 2 cycles of AC (60 mg/m2, 600 mg/m2)
given 3 weekly. Tumour responses were assessed by magnetic resonance mammography. Responders (n = 77)
received 2 further cycles of AC and were randomised to 4 cycles of T (100 mg/m2) (Group A) or T (75 mg/m2) and
X (2000 mg/m2/day), day one to 14 of each 3 weekly cycle (Group B). Non-responders (n = 35) were randomised to
6 cycles of T (Group C) or T + X (Group D). QoL questionnaires were completed at each chemotherapy visit.
Pathological responses were evaluated using established criteria.
Results: The groups were comparable in patient and tumour characteristics (79.5% T2, 85.7% ductal, 73.2%
ER +ve, 22.3% HER2 +ve, 42% involved ALNs). Overall breast pCR was 27.1%, Groups A + C versus B + D (p = 0.446).
ALN +ve pCR was 41.9%, Groups A + C versus B + D (p = 0.231). 4-year disease-free survival (DFS) was significantly
improved with X (p = 0.016) but not overall survival (p = 0.056). Triple -ve and HER2 +ve tumours, and persistent
ALN disease were risk factors for metastases. X increased severe nail changes (p = 0.0002) and hand-foot syndrome
(p = 0.014) without affecting QoL.
Conclusion: NAC-X did not increase breast and ALN pCR but improved 4-year DFS, without detriment to QoL.
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Neoadjuvant chemotherapy (NAC) is used to treat
patients with large or locally advanced breast cancers
(LLABCs), to downstage the disease and perform breast
conserving surgery (Kaufmann et al. 2012; Schott and
Hayes 2012). NAC is not detrimental to patient survival
and is comparable in efficacy with adjuvant chemo-
therapy (Schott and Hayes 2012; Mieog et al. 2007).
The addition of taxanes and trastuzumab to NAC
combinations has improved the pathological complete
response (pCR) in the breast and axillary lymph nodes
(ALNs) (Kaufmann et al. 2012; Smith et al. 2002;
Bear et al. 2006; Semiglazov et al. 2011). The addition
of capecitabine has also been studied; shown to be
effective in combination with taxanes in women with
metastatic disease (O'Shaughnessy 2002; Gluck et al.
2013).
Our study commenced in November 2008, at which
time phase 2 studies had shown increased pCR in the
breast with capecitabine combinations (Lebowitz et al.
2004; Villman et al. 2007).
A pCR in the breast and axilla is a surrogate marker
of long-term disease-free survival (DFS) and overall
survival (OS) (Kaufmann et al. 2012; Penault-Llorca
et al. 2008; von Minckwitz et al. 2012). Patients with a
breast pCR but residual cancer in the ALNs, however,
have a poor prognosis (Mazouni et al. 2007; Marchio
and Sapino 2011). A pCR in the breast occurs in 17% to
30% of patients using various anthracycline-taxane
combinations and histopathological criteria for asses-
sing pCR (Smith et al. 2002; Bear et al. 2006; von
Minckwitz et al. 2010; Walker et al. 2011). The use of
trastuzumab with human epidermal growth factor
receptor 2 positive (HER2 +ve) cancers has further
increased the pCR responses (Kaufmann et al. 2012;
Semiglazov et al. 2011).
Two studies have reported an improved pCR with
capecitabine (Lee et al. 2008; Steger et al. 2010). Three
studies failed to find an enhanced pCR (von Minckwitz
et al. 2010; Bear et al. 2012; Ohno et al. 2013). A recent
meta-analysis of anthracycline-taxane combinations did
not demonstrate any significant increase of pCR. Adding
capecitabine to NAC regimens is unlikely to improve
outcomes in breast cancer in patients without distant
metastases (Li et al. 2013). However, LLABC should be
regarded as a systemic disease with local manifestations.
Spread to ALNs carries a poor prognosis (Carter et al.
1989; Recht and Houlihan 1995). Even in the absence of
ALN invasion, 20% of women with early breast cancer
die from metastases (Fisher et al. 2010). Patients with
LLABCs are at risk of early tumour recurrence follow-
ing NAC combinations of anthracycline, taxanes and
cyclophosphamide. The Lincoln study showed a 74%
5-year DFS, whilst the NSABP-27 study a 62% 8-yearDFS (Bear et al. 2006; Walker et al. 2011). Hence, many
women without evidence of distant disease harbour
occult micro-metastases.
New NAC combinations are being evaluated to deter-
mine their effect on pCR and assess morbidity and
survival benefit (Kaufmann et al. 2012; Schott and
Hayes 2012; Colleoni and Goldhirsch 2014).
The aims of our study were to evaluate the effect of
capecitabine in anthracycline-taxane NAC combinations,
on pCR in the breast and ALNs, quality of life (QoL), DFS
and OS.Patients and methods
Patients and eligibility
Women (18–75 years) with LLABCs (≥3 cm,T3,4, N1,2,
M0) with a WHO performance of ≤2, satisfactory haem-
atological, renal, hepatic and cardiac function (absolute
neutrophil count ≥1500/μl, platelet count ≥100,000/μl;
total bilirubin <20 μmol/L, alkaline phosphatase, trans-
aminases <2 x upper limit of normal; serum creatinine
<2.0 mg/dL; left ventricular ejection fraction ≥50% by
echocardiography), were invited to participate.
Exclusion criteria were pregnancy, lactation, previous
malignancy other than basal carcinoma of skin, insulin
dependent diabetes, inability to give informed consent
or to complete QoL questionnaires.
The study was approved by the Regional Research
Ethics Committee on 24/01/2008 (Rec No: 07/H0406/
260). Participants signed an Informed Consent.Study design
Diagnosis was established by clinical examination,
mammography, ultrasonography and histological assess-
ment of needle biopsies.
Patients underwent a chest radiograph and liver
ultrasound scan (USS) or computerised tomography of
thorax and abdomen, bone scintigraphy, electrocardi-
ography, echocardiography and a magnetic resonance
mammogram (MRM) prior to commencing treatment.
QoL was assessed using validated questionnaires
(Walker et al. 2011). Prior to each cycle, and after NAC,
the Hospital Anxiety and Depression Scale (HADS),
Mood Rating Scale (MRS) and Treatment Side-Effects
Questionnaires were completed (Zigmond and Snaith
1983; Sharp et al. 2010; Walker et al. 1998). Before
cycles one, 5 and after completion of NAC, a Patient
Satisfaction Questionnaire and the Functional Assess-
ment of Cancer Therapy (Breast) (FACT-B) with Taxane
(T) modules were completed (Brady et al. 1997). The
primary QoL outcome was the Trial Outcome Index
(TOI) of FACT-B at follow-up (Brady et al. 1997).
Patient enrolment, randomisation, treatment and
assessment are outlined in the CONSORT diagram.
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Randomisation was carried out according to the MRM
response after 2 courses of NAC, using permuted
blocks. Treatment allocation was determined using sealed
sequential envelopes from Responder and Non-responder
containers.
NAC regimen
Patients received 3 weekly IV doxorubicin (A: 60 mg/m2)
and cyclophosphamide (C: 600 mg/m2) for two cycles.
Responders were randomised into Group A or B. Both
groups received 2 further 3 weekly IV AC followed by
4 cycles of IV docetaxel (T) 100 mg/m2 every 3 weeks
(Group A) or 4 cycles of IV T 75 mg/m2 and O capecitabine
(X) 2000 mg/m2/day for 14 days every 3 weeks (Group B).
Non-responders were randomised into Group C and D.
Group C received 6 cycles of IV T 100 mg/m2 every
3 weeks. Group D received 6 cycles of IV T 75 mg/m2 and
O X 2000 mg/m2/day for 14 days every 3 weeks.
Ondansetron and dexamethasone were prescribed
during and after each cycle.
Patients received lenograstim 263 μgm SC, days 2–6 after
each cycle from cycle 3 onwards. If febrile neutropenia
occurred with cycle one, lenograstim was given from cycle
2 onwards.
Surgery and radiotherapy
Prior to NAC, a radio-opaque marker was inserted into the
breast tumour, enabling needle localisation of the tumour
during breast conservation.
Wide local excision or mastectomy, according to surgical
advice (or patient preference), and either ALN sampling
(at least 4 nodes) or axillary clearance (preNAC involved
ALNs) was performed approximately 4 weeks following
chemotherapy.
Following breast conservation, patients received radio-
therapy to the breast. If node sampling established involve-
ment, the axilla and supraclavicular region were irradiated.
Following mastectomy, chest wall irradiation was given if
the patient was deemed at risk of local recurrence.
Two patients presenting with T4 tumours received radio-
therapy to the breast and draining lymph nodes prior to
surgery.
Patients whose tumours were oestrogen receptor posi-
tive (ER +ve) received tamoxifen 20 mg O daily if premen-
opausal, anastrozole 1 mg O daily/letrozole 2.5 mg O
daily if postmenopausal, for 5 years. Patients with HER2
+ve tumours underwent a 3 weekly x 18 course of IV
trastuzumab (8 mg/kg for the first two cycles, 6 mg/kg in
subsequent cycles).
Assessment of response
Clinical: Caliper measurements were carried out at each
cycle and prior to surgery. Ultrasonographic measurementswere performed after cycles 4, 6 and 8; mammograms
(MMGs) after cycles 4 and 8. RECIST criteria were used to
evaluate responses (Eisenhauer et al. 2009).
Pathological responses were evaluated in the surgical
specimens. These were graded 1 to 5 in the breast; pCR
had no invasive disease (DCIS permitted), fibroelastic scar
or hyaline amorphous area. ALNs were graded 1 to 3; pCR
had no tumour cells, with or without areas of fibrosis.
Statistical analysis
Data were analysed using SPSS v22. Pearson’s product–
moment correlations were used to explore relationships be-
tween selected variables. Between-group comparisons were
carried out at baseline using Analysis of Variance (ANOVA)
and Chi-square as appropriate, and at subsequent time-
points using Analysis of Co-variance (ANCOVA) with
baseline values as covariates (Vickers and Altman 2001).
Survival data were evaluated using Kaplan-Meier curves
and significance established using the Log Rank test. The
small number of deaths and pCRs precluded the use of
Cox proportional hazards and other multivariate methods
to identify independent prognostic factors. Analysis was by
intention-to-treat; alpha was set at <0.05 (two-tailed)
(Peduzzi et al. 1995).
Results
Treatment groups
From November 2008 to October 2011, 117 women with
LLABCs were enrolled and 112 randomised following
MRM assessment after 2 cycles of AC.
Three patients had conditions not initially detected
requiring study withdrawal. One patient withdrew due to a
severe reaction to AC and one withdrew consent after one
course of chemotherapy.
Of the 112 patients randomised, 77 (69%) were re-
sponders and were randomised to Group A (38) or B (39);
35 (31%) were non-responders and were randomised to
Group C (19) or D (16) (CONSORT diagram).
Following randomisation, two patients (Group A, B)
withdrew consent. Chemotherapy was discontinued due to
progressive disease in 6 patients: 3 after 4 cycles and 3 after
6 cycles. Ninety seven (88.2%) patients completed 7 cycles
and 92 (83.6%) 8 cycles.
One hundred and ten patients underwent surgery and
subsequent radiotherapy, as appropriate.
Patient and tumour characteristics
The ACT and ACTX therapeutic groups were comparable
in terms of age, menopausal status and tumour characteris-
tics – TNM classification, tumour size, type and grade,
nodal involvement, ER and HER2 status (Table 1).
The mean age was 53 years (range 33 to 69). Fifty-three
were pre-menopausal/ peri-menopausal, 59 post-menopausal.
The majority of tumours were T2 (79.5%), ductal invasive
Table 1 Patient and tumour characteristics of randomised patients
GROUPS A
+ C (n = 57)
STATISTICAL SIGNIFICANCE* GROUPS B
+ D (n = 55)χ2 p-value
Age in years, mean (range) 53.9 (33 – 69) - - 53.0 (35 – 69)
Menopausal status, n (%)
PRE-PERI 24 (42.1) 0.572 0.449 29 (52.7)
POST 33 (57.9) 26 (47.3)
TNM Classification, n (%)
T0-T1 2 (3.5) 1 (1.8)
T2 43 (75.4) 46 (83.6)
T3 5 (8.8) 4.881 0.300 5 (9.1)
T4 7 (12.3) 3 (5.5)
N0 32 (56.1) 29 (52.7)
N1-2 25 (43.9) 26 (47.3)
Tumour size in cm (caliper), mean (range) 4.3 (2 – 14) - - 4.2 (1.9 – 14)
Pre NAC nodal involvement, confirmed by biopsy, n (%) 22 (39.3) - - 23 (42.6)
Tumour type, n (%)
Ductal invasive 49 (86.0) 0.410 0.815 47 (85.5)
Lobular invasive (and others) 8 (14.0) 8 (14.5)
Tumour grade, n (%)
Grades 1 and 2 38 (66.7) 2.495 0.287 28 (51.0)
Grade 3 19 (33.3) 27 (49.0)
ER status, n (%)a
Positive (Allred >3) 45 (78.9) 1.732 0.421 37 (67.3)
Negative (Allred < 3) 12 (21.1) 12 (32.7)
HER2 status, n (%)b
Positive (FISH) 11 (19.3) 0.212 0.450 14 (25.9)
Negative 46 (80.7) 41 (74.1)
aER : Oestrogen receptor. bHER2: Human epidermal growth factor receptor 2. Allred : Scoring system for measuring expression of oestrogen receptors in tissue
sections. FISH : Fluorescence in-situ hybridisation.
*Various patient and tumour characteristics were not significantly different between Groups (A + C) and (B + D) (p>0.05, Pearson Chi-Square Test).
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(42.2%) patients had involved ALNs (Table 1). Seventy one
tumours were ER+ve HER2 -ve (luminal A), 15 ER+ve
HER2+ve (luminal B), 9 ER -ve PR -ve HER2+ve (HER2
overexpressing) and 15 ER -ve PR -ve HER2 -ve (basal-like).
Clinical response
Of the 110 patients who were assessed (one had involved
ALNs only), 51 in Groups A +C and 49 in B +D achieved
a CR or PR. The CR + PR in ACT was 91.9% and 92.5% in
ACTX (χ2 = 0.715, p = 0.398).
Imaging response
Ninety-five patients had lesions evaluable by ultrasonog-
raphy, whilst only 74 by digital mammography. Failure to
detect by mammography occurred in younger women and/
or in those with dense breasts. In 5 patients the
imaging assessment was incomplete.There was poor concordance between the responses
detected on ultrasonography and mammography. USSs and
MMGs were unreliable assessors of pathological responses
in the breast (data not shown).
Pathological response
Table 2 documents pathological responses in the breast;
107 breast specimens were available for assessment. The
overall pCR was 29 (27.1%); exclusion of DCIS reduced this
to 20 (18.7%). The pCR with ACT was 22.2% and with
ACTX 32.1% (χ2 = 3.717, p = 0.446). PCR occurred in 17%
of luminal A, 47% of luminal B, 33% of HER2 overexpress-
ing, and 50% of basal-like tumours. Triple negative and
HER2 +ve tumours had the highest pCR, whilst luminal A
the lowest.
Table 3 documents pathological response in ALNs;108
specimens were available for assessment. On presentation
38.6% of ALNs in Groups A +C and 41.8% in B +D
Table 2 Pathological response in breast [n (%)] following
NAC
PATHOLOGICAL RESPONSE GRADE [n(%)]b*
GROUPS (n = 107)a 5(PCR) 4(MRD) 3(PR) 2/1(PoR/NR)
A 11 (30.6) 10 (27.8) 10 (27.8) 5 (13.9)
(n = 36)
B 15 (40.5) 10 (27) 9 (24.3) 3 (8.1)
(n = 37)
C 1 (5.6) 1 (5.6) 6 (27.8) 10 (16.1)
(n = 18)
D 2 (12.5) 2 (12.5) 5 (31.3) 7 (43.8)
(n = 16)
(A + C) 12 (22.2) 11 (20.4) 15 (27.8) 16 (29.6)
(n = 54)
(B + D) 17 (32.1) 12 (22.6) 14 (26.4) 10 (18.8)
(n = 53)
aTwo patients received preoperative radiotherapy and one had no
demonstrable cancer in the breast (involved ALN on presentation).
bPCR : complete response, no residual invasive tumour cells in specimen, DCIS
accepted (grade 5); MRD : minimal residual disease, >90% loss of tumour cells,
(grade 4); PR : partial response, moderate reduction in tumour cell burden,
between 30%-90% reduction in tumour cells (grade 3); PoR : poor response,
minimal loss (<30%) of tumour cells, (grade 2); NR : no response/no change in
overall cellularity, (grade 1).
*Pathological responses were not significantly different between the Groups
(p>0.05); A + C versus (v) B + D: χ2 = 3.717, p = 0.446 (Pearson Chi-Square Test).
Table 3 Pathological response in excised axillary nodes follow
GROUPS
(n = 110)a
PATHOLOGICAL RESPONSE GRADE [n (%)]b*
3 (PCR) 2 (PR) 1(PoR)
Aa 6 (16.7%) 4 (11.1%) 4 (11.1%
n = 37
Ba 8 (21.1%) 4 (10.5%) 3 (7.9%
n = 38
C 0 (0%) 2 (11.1%) 2 (11.1%
n = 19
D 4 (25.0%) 2 (12.5%) 1 (6.25%
n = 16
A + C 6 (11.1%) 6 (11.1%) 6 (11.1%
n = 56
B + D 12 (22.2%) 6 (11.1%) 4 (7.4%
n = 54
aTwo patients had pre-operative radiotherapy and were excluded from the post NA
bPCR : complete response, all metastatic disease replaced by fibrosis (grade 3); PR :
malignant cells (grade 2); PoR : poor response, metastasis with no evidence of fibro
lymph nodes.
*Pathological responses were not significantly different between the Groups (p>0.0
ALNs): χ2 = 1.433, p = 0.231 (Pearson Chi-Square Test).
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16.7%, and 41.9% in the pre NAC involved ALNs. There
was no significant increase in pCR in either subset with
ACTX (χ2 = 2.743, p = 0.098; χ2 = 1.433, p = 0.231).
There was a 24.4% (n = 11) concurrent pCR in both the
breast and ALNs, a threefold increase with ACTX, suggest-
ing a possible benefit with capecitabine.
There were significant correlations between the patho-
logical responses in the breast and tumour grade (rxy =
0.319, p = 0.001) and HER2 status (rxy = − 0.213, p = 0.029).
NAC and toxicity
There were no deaths in the study; 13 patients experi-
enced Serious Adverse Events and one a Suspected
Unexpected Serious Adverse Reaction. The anticipated
side-effects of chemotherapy (alopecia, nausea, vomiting,
excess lacrimation, blood-stained nasal discharge and
fatigue) were commonly seen, treated as appropriate,
and were well tolerated by most patients.
Twenty-four patients had 28 episodes of febrile
neutropenia requiring hospitalisation for one to 6 days; 24
occurred during the first two cycles prior to commencing
lenograstim. Lenograstim substantially reduced the inci-
dence of febrile neutropenia, preventing delays in treat-
ment and minimising the need for dose reduction.
Grade 3/4 toxicities following completion of 8 cycles of
NAC are shown in Table 4.
Pronounced fatigue was very common (>50%) but was
comparable between groups (χ2 = 1.813, p = 0.612).








ALNs (n = 45)
POST NAC PCR
in ALNs (n = 43)a
) 21 (55.3%) 17 (44.7%) 6 (35.3%)
) 23 (60.5%) 15 (39.5%) 8 (53.3%)
) 14 (77.8%) 5 (26.3%) 0 (0%)
) 9 (56.3%) 8 (50%) 4 (50%)
) 35 (61.4%) 22 (38.6%) 6 (30%) (n = 20)
) 32 (58.2%) 23 (41.8%) 12 (52.2%) (n = 23)
C analysis, one in Group A and one in Group B.
partial response in metastatic disease and evidence of fibrotic replacement of
sis (grade 1); normal nodes: no evidence of metastatic disease or fibrosis in
5); A + C v B + D (all ALNs): χ2 = 2.743, p = 0.098; A + C v B + D (pre NAC +ve




NAILS* HAND-FOOT* PARESTHESIA MYALGIA* FATIGUE
A 6(20.0%) 1 (3.3%) 2 (6.6%) 7 (23.3%) 16 (53.3%)
(n = 30)
B 16 (47.1%) 7 (23.3%) 1 (2.9%) 1 (2.9%) 21 (61.7%)
(n = 34)
C 1 (6.3%) 0 (0%) 2 (12.5%) 1 (6.3%) 9 (56.3%)
(n = 16)
D 8 (66.7%) 1 (8.3%) 2 (16.6%) 0 (0%) 9 (75.0%)
(n = 12)
(A + C) 7 (15.2%) 1 (2.2%) 4 (8.7%) 8 (17.4%) 25 (54.3%)
(n = 46)
(B + D) 24 (52.2%) 8 (17.4%) 3 (6.5%) 1 (2.2%) 30 (65.2%)
(n = 46)
aSerious Adverse Events (SAEs) : n = 13; Suspected Unexpected Serious Adverse Reactions (SUSARs) : n = 1; Deaths : n = 0. NS : Not Significant.
*Statistically significant (Pearson Chi-Square Test). *Nail changes : A v B (χ2 = 5.173, p = 0.023); C v D (χ2 = 11.476, p = 0.007); A + C v B + D (χ2 = 14.060, p = 0.0002).
*Hand-foot syndrome : A v B (χ2 = 4.338, p = 0.037); C v D (NS); A + C v B + D (χ2 = 6.035, p = 0.014). Paresthesia : A v B (NS); C v D(NS); A + C v C + D (NS). *Myalgia :
A v B (χ2 = 9.572, p = 0.023); A + C v B + D (χ2 = 6.035, p = 0.014). Fatigue : A v B (NS); C v D (NS); A + C v B + D (NS).
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Groups A + C versus B + D (χ2 = 6.035, p = 0.014). Severe
paresthesia occurred in <20% and was comparable
between groups (χ2 = 3.037, p = 0.386).
Severe hand-foot syndrome was more common, with the
use of X: Groups A +C versus B +D (χ2 = 6.035, p = 0.014).
Severe nail changes were very common, predominantly
in patients receiving X: Groups A + C versus B + D (χ2 =
14.060, p = 0.0002).
QoL and NAC
The primary QoL outcome was the TOI of FACT-B.
Groups A + C and B + D did not differ at baseline
(F = 0.407, df = 1, p = 0.482), before cycle 5 (F = 0.921,
df = 2, p = 0.339) or at follow-up (F = 0.022, df = 2, p =
0.882). In addition, there were no significant differencesTable 5 Significant (2-tailed) correlations between various pa
PSYCHOLOGI





CLINICAL RESPONSE IN BREAST TO NAC HADS (DEPRES
MRS (HAPPINE
MRS (CLEAR H
PATHOLOGICAL RESPONSE IN BREAST TO NAC MRS (CLEAR H
MRS (CONFIDE
aHADS : Hospital anxiety and depression scales; MRS : Mood rating scales.
*rxy : Pearson Correlation (Univariate Analysis of Variance).at any of these three time-points for any of the FACT
subscales (Physical, Social, Family, Emotional and Func-
tional well-being, Breast Cancer and Taxane).
Similarly, Groups A + C and B + D did not differ at any
time-point on any of the secondary outcome measures.
TNM tumour (T) correlated positively with anxiety
(rxy = 0.296, p = 0.001) and depression (rxy = 0.291, p =
0.002), and negatively with happiness (rxy = −0.185, p =
0.049), clear headedness (rxy = −0.249, p = 0.008) and
relaxation (rxy = −0.236, p = 0.011) (Table 5).
Clinical response correlated positively with depression
(rxy = 0.218, p = 0.020), and negatively with clear headed-
ness (rxy = −0.217, p = 0.021) and happiness (rxy = −0.217,
p = 0.021).
Pathological response correlated positively with clear
headedness (rxy = 0.263, p = 0.010) and confidencerameters in women with LLABCs undergoing NAC













Figure 1 Kaplan-Meier Survival curves for (A) DFS (χ2 = 5.802,
df1, p = 0.016) and (B) OS (χ2 = 3.639, df1, p = 0.056) at a
median follow-up period of 4 years and 3 months (Log Rank
[Mantel-Cox]).
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Metastatic disease and survival
The first patient was randomised in December 2008 and
the last in October 2011. Following randomisation, 110
patients were followed-up from 30 to 64 months – 56
patients in Groups A + C and 54 in Groups B +D.
Twelve patients (21.2%) who received ACT and 3 (5.6%)
ACTX have developed metastases (liver, lung, bone,
brain): 8 (14.3%) who received ACT and 2 (3.7%) ACTX
have died. Patients with basal-like (triple -ve) and HER2
overexpressing tumours were at high risk of developing
metastases.
No patient who had a pCR in the breast and ALNs
(n = 11) developed metastases. ALN pCR was associated
with a very low risk of developing metastases (1/18
patients). Persistent ALN disease was associated with a
significant risk of developing metastases (10/25 patients).
The Kaplan-Meier DFS and OS (median follow-up of
51 months) are shown in Figure 1. Patients who received
ACTX had a significantly increased DFS (Log Rank χ2 =
5.802, p = 0.016). There were fewer events in OS, but there
was a tendency for an improved short-term survival (Log
Rank χ2 = 3.639, p = 0.056).
Discussion
PCR in the breast following NAC is a surrogate marker of
improved survival (Kaufmann et al. 2012; von Minckwitz
et al. 2012). In our study, pCR in the breast was defined as
absence of invasive disease with or without ductal carcin-
oma in situ (DCIS). Various studies (5 to 10 year follow-
up) have documented no change in DFS or OS in the
presence of DCIS (Penault-Llorca et al. 2008; Mazouni
et al. 2007; Marchio and Sapino 2011; Jones et al. 2006).
Cancer spread to ALNs results in poor survival and in-
dicates systemic dissemination (Carter et al. 1989; Recht
and Houlihan 1995). Residual disease in ALNs following
NAC has a bad prognosis, even with a pCR in the breast
(von Minckwitz et al. 2012; Marchio and Sapino 2011).
PCR in the ALNs carries an excellent prognostis, even
with residual invasive disease in the breast (von Minckwitz
et al. 2012; Mazouni et al. 2007; Hennessy et al. 2005).
The best DFS and OS occur when there is pCR in both
the breast and axilla (von Minckwitz et al. 2012; Mazouni
et al. 2007).
To achieve an improved pCR, various NAC combinations
have been used, including capecitabine with anthracyclines
and taxanes. The rationale for the use of capecitabine is the
improved OS and time to disease progression with TX in
advanced disease (O'Shaughnessy 2002; Gluck et al. 2013).
Two studies have reported an increased pCR in the breast
with NAC-X combinations (Lee et al. 2008; Steger et al.
2010). Three others have failed to do so (von Minckwitzet al. 2010; Bear et al. 2012; Ohno et al. 2013). Our findings
are in agreement with these latter results. Exclusion of
DCIS reduced pCR responses to that documented by
others using similar criteria (von Minckwitz et al. 2010).
Studies evaluating ALNs following NAC without cape-
citabine have documented a pCR of around 23% (Kuerer
et al. 1999; Rouzier et al. 2002). Studies with NAC-X have
shown no improvement (von Minckwitz et al. 2010; Bear
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ings. Eleven patients with involved ALNs had a pCR in
both nodes and breast; there was an almost 3-fold increase
in those receiving ACTX.
Thirteen percent of the tumours were basal-like, com-
parable with other studies (Dent et al. 2007; Carey et al.
2007). These had the highest pCR (50%) as previously
documented (Colleoni and Goldhirsch 2014; Colleoni
et al. 2004). HER2 +ve tumours (luminal B, HER2 overex-
pressing) also elicited high levels of pCR, in agreement
with published studies (Carey et al. 2007; Oh et al. 2006).
The lowest pCR (17%) occurred in luminal A (ER +ve)
tumours and is well established (Carey et al. 2007;
Colleoni et al. 2004; Precht et al. 2010). Our study showed
a significant correlation between pathological responses in
the breast and tumour grade and HER2 status.
Two recent adjuvant studies did not demonstrate an
improved 5-year DFS or OS with capecitabine (Ohno
et al. 2013; Joensuu et al. 2012). However, patients with
triple -ve cancers or 3 involved ALNs had an improved
5-year DFS and OS with capecitabine (Joensuu et al.
2012). Another study showed an increased OS but not
DFS (O'Shaughnessy et al. 2009). A recent meta-analysis
suggested an increased 5-year DFS and OS with adjuvant
capecitabine (Jiang et al. 2012). In our study, capecita-
bine significantly improved the 4-year DFS (p = 0.016),
but the OS just failed to reach significance (p = 0.056),
probably due to the small number of deaths. Patients
with basal-like and HER2 overexpressing tumours were
at highest risk of metastases.
In metastatic disease the best results are obtained with
TX (O'Shaughnessy 2002; Gluck et al. 2013). In our
study, 84% completed 8 cycles of NAC. Of 55 patients
receiving TX, 60% had a full dose. This is comparable to
studies reporting no improved DFS with capecitabine
(Ohno et al. 2013; Joensuu et al. 2012; O'Shaughnessy
et al. 2009). Our planned dose of T was similar to that
in two of the above trials, but 40-60% higher than in the
third study. Our planned dose of X was 20-50% higher
than in these three trials (Ohno et al. 2013; Joensuu
et al. 2012; O'Shaughnessy et al. 2009).
The pattern and severity of the toxicity in our trial is
comparable with other studies (Ohno et al. 2013; Joensuu
et al. 2012). Severe hand-foot syndrome and nail changes
were seen predominantly in patients receiving ACTX.
Lenograstim substantially reduced the incidence of febrile
neutropenia thereby contributing to reduced side-effects
and improved QoL, as documented previously (Martin
et al. 2006).
QoL did not differ significantly between groups on the
primary outcome measures (FACT-B TOI) at any time
point. The other measures of QoL in the various groups
were comparable. The improved 4-year DFS did not
occur at the expense of QoL.Tumour stage at trial entry was positively correlated with
HADS anxiety and depression and negatively with MRS
happiness, clear headedness and relaxation, highlighting
that women with LLABCs were distressed. This may have
been due to their disease stage and proposed treatment, or
biopsychological effects by the tumour (Walker et al.
2005). At baseline, depression correlated positively and
mood (happiness, clear headedness) negatively, with clin-
ical response to NAC; the more distressed the patient, the
poorer the clinical response. Three weeks after completion
of NAC, pathological response correlated positively with
clear headedness and confidence. We have previously
reported these relationships in women with LLABC under-
going NAC (different combination) and shown that
distress was an independent prognostic factor for clinical
and pathological responses (Walker et al. 1999).
Pathological response to NAC also correlated posi-
tively with tumour grade, and HER2 status.
Our study suggests a distinct benefit with NAC-X, with
the doses of TX used in our trial, in patients with
LLABCs. Further NAC studies with follow-up are needed
to establish optimal TX delivery in patients at high risk to
improve DFS and OS.
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